Treating human disease at the genetic level, by replacing defective genes or adding new genes to enhance native functions, has been a long-standing goal, with the first attempts at gene editing dating back to the 1980s1. However, it wasn’t until 2012 that momentum in the field surged, thanks to the discovery of the CRISPR/Cas9 genome […]
The success of chimeric antigen receptor (CAR)-T cell therapy has spurred interest in applying CAR technology to other immune cells in hopes of addressing some known limitations. With their intrinsic immune activity and favorable safety profile, natural killer (NK) cells have enormous potential for adoptive cellular therapy1. Unlike T cells, which require antigen sensitization and […]
The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability to isolate specific cell types from heterogeneous tissue or blood-derived sources such as whole peripheral blood, bone marrow, or cord blood is critical to advancing […]
By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is impressive given that the first CAR-T therapies only gained US Food and Drug Administration (FDA) approval in 2017 and demonstrates the power of these new […]
After a decade of innovation, chimeric antigen receptor (CAR)-T cell therapy remains at the forefront of the cell and gene therapy space, continuing to forge new ground to treat previously intractable cancers and diseases (Figure 1). Since 2017, six CAR-T cell therapies have been approved by the Food and Drug Administration (FDA) and all are […]
Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo and ex vivo strategies to modify target cells. Ex vivo therapies that involve isolating cells from a patient (autologous) or a donor (allogeneic) and modifying […]
Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed year where clinical progress, continued growth, and segmentation into new disease areas affecting larger patient populations is anticipated. With over 2,600 active clinical trials in 2021, the clinical pipeline is maturing at a rapid pace. Forty three percent of […]
In the past decade, emerging therapeutic modalities like cell and gene therapies have opened up new treatment options for previously intractable diseases, changing the industry needs for primary tissues. While autologous therapies—which are created using a patient’s own cells—still dominate the field, many cell and gene developers are investing in allogeneic therapies that can be […]
Primary cells, such as those isolated from the bone marrow or peripheral blood, are important for a wide scope of research and clinical applications – from studying molecular mechanisms driving disease progression, to developing ex vivo therapies in regenerative medicine. Unlike immortalized cell lines, primary cells have a finite lifespan in culture and can undergo unwanted changes like genetic drift and […]
Adoptive cell therapies (ACTs), which is a treatment based on transferring cells (most often immune cells) into a patient, have revolutionized the standard of care to treat a broad range of diseases. It has perhaps made the most impact in cancer immunotherapy where the successes of chimeric antigen receptor (CAR) T cell therapies to treat […]
